Scientists have found a way to prevent migraine headache


Shot of a uncomfortable looking woman holding her head in discomfort due to pain at home during the day

Prevent migraine headache– changing the body’s molecules using a small inhaler, scientists have found that treating headaches without medicine is a chance.

 Patients suffering migraines can either bring down their utilization of medicine or cut it out totally by marginally changing the molecules of their body utilizing a little inhaler.

The investigation recommends another and innovative way of treating migraines and opens up an entirely new world of neurology.

Frequency of migraines

Johansen clarifies that migraines happen as a component of a chain response during which the veins in the mind contract and the blood can’t hence flexibly the cerebrum with adequate oxygen. The inhaler has been intended to facilitate the progression of oxygen to the cerebrum, basically diminishing the event of agony and treating headache.

“The inhaler expands the blood vessels that supply the brain with oxygen by up to seventy per cent and thereby stops the destructive chain reaction.”

He adds that the effect of the treatment starts after a few seconds.

“We utilise CO2 and oxygen, which are the body’s natural molecules for mobilising its own defence against migraine attacks.”

 Scientists have developed a new drug to prevent migraines. The drug called Erenumab consists of human works by targeting a receptor in the brain. Where a protein associated with migraines usually binds.

This protein transmits migraine pain signals during an attack.

Erenumab is an injectable drug that blocks receptor thus preventing a migraine attack.  The drug reduced the number of monthly migraine attacks by more than 50%.

No known side effects of this drug were recorded in human patients.

Migraine is a neurological disorder. characterized by a servere throbbing pain on one or both sides of the head.

In some cases, head pain may be accompanied by other symptoms.

Including nausea, vomiting, numbness, or tingling in the face.

Patients may also experience sensitivity to light and sound and vision problems. There are four main phases of a migraine .

Phase 1: The prodrome, where a trigger inside or outside your body. Causes an abnormal firing of neurons in the brain. In can begin hours or days before the actual migraine starts.

Phase 2: The Aura phase, which includes temporary visual or sensory distrubances. That usually strike before other migraine symptoms.Abnormal neuronal firing leads to a wave of electrical hyperactivity. That moves across part of the brain that processes signals from your senses.

Once the electrical waves stop,the aura goes away.

Not everyone experiences an aura when having a migraine .

Only 20-25% of migrane sufferers experience aura.

Phase 3: The attack phase,also known as the headache phase. This is when the actual headache strikes and can last for hours up to several days.

The abnormal firing of neurons activates the Trigeminal nerve. which surrounds the blood vessels in your head.

This nerve is responsible for motor functions and sensation in the face.

The attack phase leads to the release of inflammatory substances.

That causes your blood vessels to swell.

Leading to an increase in blood flow around the brain. This is the cause of throbbing pulsing pain most people experience during a migraine.

Pain receptors are then activated to send pain signals to different parts of the brain.

If untreated, migraines can last up to 72hours.

Before the nervous system response finally quiets.

Phase 4: The postdrome or recovery phase where nonheadache symptoms.

Like fatigue, weakness, and impaired concentration can continue for 1-2 days.

Until your brain returns to its normal,pre-activation state.



Erenumab in chronic migraine

To decide the impact of Erenumab, a human monoclonal immuniser focusing on the calcitonin quality-related peptide receptor, on wellbeing related personal satisfaction (HRQoL), cerebral pain effect, and incapacity in patients with persistent headache (CM).o assess the viability and security of erenumab as preventive treatment in patients with headache utilizing meta-investigative methods.

The monoclonal antibody appears to reduce the impact of migraine on everyday activity and physical function.

Erenumab reduces the number of migraine days out of every month in patients with verbose migraine, as indicated by an examination introduced at the 69th Annual Meeting of the American Academy of Neurology. The treatment likewise diminishes the utilization of intense headache prescription and improves work.

Erenumab is a completely human monoclonal immunizer created to hinder the pathway of calcitonin quality-related peptide (CGRP). The therapy indicated guarantee in stage II concentrate in patients with long-winded headache and in a stage II investigation of patients with ongoing migraine, as per Peter Goadsby, MD, Ph.D., Professor of Neurology at the University of California, San Francisco School of Medicine.


Leave a Reply

Your email address will not be published. Required fields are marked *

error: Content is protected !!